Saudi journal of anaesthesia
2024
Ugrani S Rani, Nidhi B Panda, Rajeev Chauhan et al.
11 citations
Opioids form the basis of perioperative pain management but are associated with multiple side effects. In opioid-free anesthesia (OFA), several non-opioid drugs or neuraxial/regional blocks are used as substitutes for opioids. Ketamine, a N-methyl-d-aspartate antagonist, provides intense analgesia. However, there is a shortage of literature on the effects of ketamine-based OFA on hemodynamics...
Frontiers in Molecular Neuroscience
2024
Dionnet L Bhatti, Junghee Jin, Jia Cheng et al.
4 citations
The prefrontal cortex (PFC) is a key neural node mediating behavioral responses to stress and the actions of ketamine, a fast-acting antidepressant. The molecular mechanisms underlying these processes, however, are not fully understood. Our recent study revealed a pivotal role of hippocampal Ahnak as a regulator of cellular and behavioral adaptations to chronic stress. However, despite its...
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2024
D V Kurkin, E I Morkovin, D A Bakulin et al.
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in...
Frontiers in Pharmacology
2024
Xulin Chen, Xian Wang, Caijuan Li et al.
7 citations
There have been numerous studies on NMDA receptors as therapeutic targets for depression. However, so far, there has been no comprehensive scientometric analysis of this field. Thus, we conducted a scientometric analysis with the aim of better elucidating the research hotspots and future trends in this field. Publications on NMDAR in Depression between 2004 and 2023 were retrieved from the Web...
Frontiers in Psychiatry
2024
Giulia Menculini, Gianmarco Cinesi, Francesca Scopetta et al.
10 citations
Major depressive disorder (MDD) represents a major health issue in adolescents and young adults, leading to high levels of disability and profoundly impacting overall functioning. The clinical presentation of MDD in this vulnerable age group may slightly differ from what can be observed in adult populations, and psychopharmacological strategies do not always lead to optimal response. Resistance...
Revista Colombiana de psiquiatria
2024
María Del Mar Arango-Posada, Ana Isabel Prada-Escobar, Carolina Marín-Hernández et al.
Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes. We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a...
Frontiers in Neuroscience
2024
Tim Simon Neuhäusel, Zoltan Gerevich
5 citations
N-methyl-D-aspartate (NMDA) receptor antagonists are widely used to pharmacologically model schizophrenia and have been recently established in the treatment of treatment-resistant major depression demonstrating that the pharmacology of this substance class is complex. Cortical gamma oscillations, a rhythmic neuronal activity associated with cognitive processes, are increased in schizophrenia...
General Hospital Psychiatry
2024
Jeong Hoo Lee, Joji Suzuki
4 citations
While the majority of patients with catatonia fully respond to benzodiazepines or ECT, some have a partial or no response. Benzodiazepines may be contraindicated such as when delirium co-exists. This review discusses the utility of NMDA receptor antagonists as alternatives to benzodiazepines in the treatment of catatonia in adults. A PubMed search adhering to PRISMA guidelines was conducted for...
International Journal of Psychiatry in Clinical Practice
2024
Marie Spies, Siegfried Kasper, Richard Frey et al.
Modern electroconvulsive therapy (ECT) and ketamine currently represent the most effective treatment options in depressed patients showing non-response to two or more trials of antidepressants. Recently, large sample head-to-head comparisons of intravenous ketamine versus ECT for treatment-resistant depression (TRD) have fuelled the debate on which therapy might be more effective. However, the...
Advances in experimental medicine and biology
2024
Berend Olivier, Jocelien D A Olivier
11 citations
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people (ca. 30%) fails to respond to first-line treatment, resulting in treatment-resistant depression (TRD). Although non-response to multiple antidepressant...